When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALBO - Albireo's A4250 shows positive action in mid-stage pediatric cholestasis study
Albireo Pharma Inc.
An open-label Phase 2 clinical trial evaluating Albireo Pharma's (ALBO-3.9%) lead candidate A4250 in pediatric Alagille syndrome and biliary atresia patients for the treatment of cholestasis (restricted or blocked bile flow) showed a positive effect. The results were presented at The International Liver Congress in Vienna.
More news on: Albireo Pharma, Inc., Healthcare stocks news,